Design of a phase 0 microdosing trial for correlation of platinum-induced DNA damage to chemotherapy outcomes
Journal of Clinical Oncology May 20, 2009 C. Pan, T. Li, M. He et al.
2543 Background: DNA damage is the critical step in cancer cell response to platinum (Pt) chemotherapy. We hypothesize that low levels of Pt-induced DNA damage are predictive of chemoresistance. Accelerator mass spectrometry (AMS), an ultrasensitive method for measuring radiocarbon, can detect [14C]carboplatin bound to the DNA of cancer cells from cell culture, mice bearing tumor xenografts and...